Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder

• Status: Not yet recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder on buprenorphine or methadone treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborators: Harvard Medical School; Harvard Medical School (HMS and HSDM)
• Treatments: Cannabidiol; Epidiolex

Criteria

Inclusion Criteria

• English speaking

• DSM5 diagnosis of opioid use disorder

• Receiving buprenorphine or methadone for treatment of opioid use disorder

• Agreeable to abstaining from using any cannabis or CBD products for the duration of the trial.

Exclusion Criteria:

• Any self-reported use of cannabis or CBD products in the past 30 days

• Baseline depression (PHQ9) or anxiety (GAD7) scores of greater than 10

• Currently pregnant

• Hepatic liver enzymes greater than 3x upper normal limit

• Hypersensitivity to cannabinoids or sesame oil (CBD solution comes in sesame oil emulsion)

• Currently taking any medications with known significant pharmacokinetic interactions with CBD